Objective： To investigate the effect of Chinese recipe, Wuye Decoction （五叶汤, WYD）, on immune function in patients with non-small cell lung cancer （NSCLC）. Methods： Eighty-two patients of NSCLC with pathologic...Objective： To investigate the effect of Chinese recipe, Wuye Decoction （五叶汤, WYD）, on immune function in patients with non-small cell lung cancer （NSCLC）. Methods： Eighty-two patients of NSCLC with pathologically confirmed diagnosis, who had received operative treatment and completed the post-operational chemotherapy, were randomly assigned into 2 groups. Group A （42 cases） received WYD and Group B （40 cases） received no specific medicine. Positive rate of various peripheral lymphocyte subsets, including CD3, CD4, CD8, CD16, CD19 and CD25, in both groups was observed immediately after chemotherapy （To） and 3 months later （T1）, the same indexes of 20 healthy volunteers allocated in Group C were also determined at To for control. Results： The positive rates of CD4, CD4/CDS, 0D16, 0D19 and CD25 were significantly lower （P〈0.05） while that of CD8 was significantly higher （P〈0.05） in Group A and B at To than those in Group C; at T1, these indexes, except CD25, got significantly restored in Group A with the level approaching normal range （ P〉0.05）, and showed significant difference from those in Group B （P〈0.05）, since these indexes in that group remained unchanged at the corresponding period. As for CD25, it was insignificantly changed in Group A after WYD treatment, and thus, at T1, it was still lower than that in Group C （P〈0.05） and showed insignificant difference as compared with that in Group B （ P〉0.05）. Comparison of CD3 among the 3 groups showed no significant difference （P〉0.05）. Conclusion： WYD could activate the immune function of NSCLC patients, and so it is recommended to be used in the treatment of NSCLC in clinical practice.展开更多
文摘Objective： To investigate the effect of Chinese recipe, Wuye Decoction （五叶汤, WYD）, on immune function in patients with non-small cell lung cancer （NSCLC）. Methods： Eighty-two patients of NSCLC with pathologically confirmed diagnosis, who had received operative treatment and completed the post-operational chemotherapy, were randomly assigned into 2 groups. Group A （42 cases） received WYD and Group B （40 cases） received no specific medicine. Positive rate of various peripheral lymphocyte subsets, including CD3, CD4, CD8, CD16, CD19 and CD25, in both groups was observed immediately after chemotherapy （To） and 3 months later （T1）, the same indexes of 20 healthy volunteers allocated in Group C were also determined at To for control. Results： The positive rates of CD4, CD4/CDS, 0D16, 0D19 and CD25 were significantly lower （P〈0.05） while that of CD8 was significantly higher （P〈0.05） in Group A and B at To than those in Group C; at T1, these indexes, except CD25, got significantly restored in Group A with the level approaching normal range （ P〉0.05）, and showed significant difference from those in Group B （P〈0.05）, since these indexes in that group remained unchanged at the corresponding period. As for CD25, it was insignificantly changed in Group A after WYD treatment, and thus, at T1, it was still lower than that in Group C （P〈0.05） and showed insignificant difference as compared with that in Group B （ P〉0.05）. Comparison of CD3 among the 3 groups showed no significant difference （P〉0.05）. Conclusion： WYD could activate the immune function of NSCLC patients, and so it is recommended to be used in the treatment of NSCLC in clinical practice.
